Drug Profile
Research programme: NASH therapeutics - La Jolla
Latest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company
- Developer La Jolla Pharmaceutical Company; Stanford University
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva
- 28 Jul 2018 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 16 Jun 2014 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)